CEOs share lessons learned in biotech

Last week I attended Pennsylvania BIO's CEO Roundtable event, where Cephalon's Frank Baldino, Prism Pharmaceuticals' Warren Cooper and Fujirebio Diagnostics' Paul Touhey spoke to a room packed with the biotech industry's rank-and-file. They shared their thoughts on drug development, generic biologics, the current economic environment and managing biotech talent. Here's what they had to say. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.